New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 15, 2014
13:35 EDTLXRXLexicon study shows LX4211 lessens postprandial glucose levels
Lexicon Pharmaceuticals presented data at the 74th Scientific Sessions of the American Diabetes Association, ADA, in San Francisco on LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2, SGLT1 and SGLT2, that is designed to lower blood glucose levels through two insulin-independent mechanisms of action. Results presented from a clinical study showed that LX4211 significantly reduced postprandial glucose levels in type 2 diabetes patients with moderate to severe renal impairment.
News For LXRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for LXRX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use